ABSTRACT BACKGROUND: Infliximab (IFX) therapeutic drug monitoring is an important tool to guide therapeutic decision in inflammatory bowel disease patients. Currently, there are two methods to measure trough levels of IFX, ELISA assays or rapid tests. Despite that the ELISA assay is the most used metho...
Edad de Inicio,
Anticuerpos/sangre,
Biomarcadores/sangre,
Estudios de Cohortes,
Colitis Ulcerosa/sangre,
Enfermedad de Crohn/sangre,
Estudios Transversales,
Monitoreo de Drogas,
Ensayo de Inmunoadsorción Enzimática,
Fármacos Gastrointestinales/sangre,
Infliximab/sangre,
Persona de Mediana Edad,
Curva ROC,
Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
ABSTRACT Janus kinases inhibitors have already been incorporated into the management of immune-mediated diseases, such as rheumatoid arthritis, and are being investigated for the treatment of psoriasis and inflammatory bowel diseases, both ulcerative colitis and Crohn's disease. Tofacitinib is an oral sm...
INTRODUCCIÓN: La Enfermedad Inflamatoria Intestinal (EII) es un grupo de patologías crónicas que tiene implicancias en diversos factores que afectan la calidad de vida en el paciente pediátrico. OBJETIVOS: Describir la calidad de vida relacionada con la salud (CVRS) en pacientes pediátricos con Enf...
Summary Objective: The aim of our study was to assess body composition status and its association with inflammatory profile and extent of intestinal damage in ulcerative colitis patients during clinical remission. Method: This is a cross-sectional study in which body composition data (phase angle [PhA]...
Biomarcadores/metabolismo,
Sedimentación Sanguínea,
Composición Corporal/fisiología,
Índice de Masa Corporal,
Proteína C-Reactiva/análisis,
Colitis Ulcerosa/fisiopatología,
Estudios Transversales,
Hemoglobinas/análisis,
Persona de Mediana Edad,
Músculo Esquelético/fisiología,
Evaluación Nutricional,
Estado Nutricional/fisiología,
Orosomucoide/análisis,
Índice de Severidad de la Enfermedad
Ulcerative colitis (UC) is an autoimmune inflammatory chronic disease, which compromises
the colonic mucosa continuously, affecting the rectum with a variable proximal extension
to the cecum, in a relapsing and remitting way. The higher incidences and prevalence are
described in Europe and North America,...
Biological therapies have been essential for the management of inflammatory bowel disease; however, their
high cost results in many patients being unable to access them. With time, commercial patents of many
“original” biologics are reaching or almost in the point of reaching the expiration date of t...
Introducción. La enfermedad inflamatoria intestinal (EII) comprende la colitis ulcerosa (CU) y la enfermedad de Crohn (EC). Su diagnóstico es cada vez más frecuente en pediatría y la incidencia es desconocida en Argentina. El objetivo de este trabajo fue determinar la incidencia anual de EII en menor...
ABSTRACT BACKGROUND: Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases. In such pathologies, there is an increased production of alpha tumor necrosis factor (TNF-α). Patients, in whom the conventional immunosuppressant treatment fails, require the use of immunobiologica...
Estudios de Cohortes,
Colitis Ulcerosa/sangre,
Colitis Ulcerosa/tratamiento farmacológico,
Enfermedad de Crohn/sangre,
Enfermedad de Crohn/tratamiento farmacológico,
Estudios Transversales,
Fármacos Gastrointestinales/sangre,
Fármacos Gastrointestinales/uso terapéutico,
Infliximab/sangre,
Infliximab/uso terapéutico,
Persona de Mediana Edad,
Estudios Retrospectivos,
Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
Zacharias, Patrícia;
Damião, Aderson Omar Mourão Cintra;
Moraes, Antonio Carlos;
Teixeira, Fábio Vieira;
Ludvig, Juliano Coelho;
Nones, Rodrigo Bremer;
Saad-Hossne, Rogerio;
Sassaki, Ligia Yukie;
Silva, Rosemary Pereira Lino da;
Facchin, Luiza;
Olandoski, Marcia;
Kotze, Paulo Gustavo.
ABSTRACT BACKGROUND: Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. OBJ...
ABSTRACT Surgery for ileoanal pouch has evolved dramatically over the last 30 years. Many of the advances relate to minimally invasive approaches that not only offer cosmetic benefits but also have advantages that are well described in the literature. In this technical note, the authors describe the doub...
